BMY Stock: Bristol Myers Buying RayzeBio For $4.1 Billion; RYZB Soars

Bristol Myers Squibb (BMY) said Tuesday it would acquire cancer drug developer RayzeBio (RYZB) in a deal valued at $4.1 billion. RYZB stock soared 100% on the news while BMY stock traded slightly lower. Bristol Myers will pay $62.50 per share for RayzeBio, a 104% premium to the company's Friday…#bristolmyerssquibb #bmy #rayzebio #ryzb #bristolmyers #sandiego #samithirawat #astrazeneca #azn #creamofcrop
Source: Reuters: Health - Category: Consumer Health News Source Type: news